Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Rate and Predictors of Prescription of Lumacaftor – Ivacaftor in the 18 Months Following Approval in the United States

Rate and Predictors of Prescription of Lumacaftor – Ivacaftor in the 18 Months Following Approval in the United States

Resource Type

CF Research News

Authors

Gregory S. Sawicki, Aliza K. Fink, Michael S. Schechter, Deena R. Loeffler, Nicole Mayer-Hamblett

References

J Cyst Fibros. 2018 Sep 7. pii: S1569-1993(18)30755-0. doi: 10.1016/j.jcf.2018.08.007.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Date

Friday, September 7, 2018

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [3]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/rate-and-predictors-prescription-lumacaftor-%E2%80%93-ivacaftor-18-months

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-18-00229R1_FINAL_Sawicki_270918%20%28002%29.pdf [2] https://www.ncbi.nlm.nih.gov/pubmed/30201329 [3] https://www.ecfs.eu/resource-guideline-type/other-guidelines